Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy
المؤلفون المشاركون
Osaka, Kimito
Makiyama, Kazuhide
Miyamoto, Hiroshi
Miyoshi, Yasuhide
Teranishi, Jun-ichi
Yao, Masahiro
Uemura, Hiroji
Ohtake, Shinji
Kasahara, Ryo
Hattori, Yusuke
Mizuno, Nobuhiko
Umemoto, Susumu
Nakaigawa, Noboru
Ito, Hiroki
Kawahara, Takashi
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-09-08
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Introduction and Objectives.
Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients.
We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy.
In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy.
Methods.
A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study.
The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality.
Results.
The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality.
Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively.
Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p=0.011) and OS (p=0.045).
Conclusions.
NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ohtake, Shinji& Kawahara, Takashi& Kasahara, Ryo& Ito, Hiroki& Osaka, Kimito& Hattori, Yusuke…[et al.]. 2016. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International،Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ohtake, Shinji…[et al.]. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International No. 2016 (2016), pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ohtake, Shinji& Kawahara, Takashi& Kasahara, Ryo& Ito, Hiroki& Osaka, Kimito& Hattori, Yusuke…[et al.]. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1099416
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر